Literature DB >> 4762550

Prekallikrein deficiency in man.

K D Wuepper.   

Abstract

Blood plasma obtained from an individual with abnormal thromboplastin formation, due to deficiency of Fletcher factor, was fully corrected by 2% of normal, Hageman factor- or PTA-deficient plasma. It was also reconstituted by addition of highly purified human or rabbit prekallikrein. The plasma failed to generate kinin upon exposure to kaolin, a defect which was also corrected by addition of prekallikrein. Prekallikrein antigen was not detectable in this plasma. Fletcher factor-deficient plasma did not support the normal generation of PF/dil when dilute plasma was incubated in glass vessels and injected intracutaneously. Small quantities of Fletcher factor-deficient or Hageman factor-deficient plasma corrected the ability of the other to generate PF/dil. The formation of plasmin in dilute, acidified plasma incubated with kaolin was also abnormal in Fletcher factor-deficient plasma. Plasmin generation was normalized by addition of prekallikrein or small quantities of Hageman factor-deficient plasma. The data support the identity of Fletcher factor and prekallikrein.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4762550      PMCID: PMC2139450          DOI: 10.1084/jem.138.6.1345

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  10 in total

1.  THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR.

Authors:  O D RATNOFF; A A MILES
Journal:  Br J Exp Pathol       Date:  1964-06

2.  A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma.

Authors:  O D RATNOFF; J E COLOPY
Journal:  J Clin Invest       Date:  1955-04       Impact factor: 14.808

3.  Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation.

Authors:  J MARGOLIS
Journal:  J Physiol       Date:  1958-11-10       Impact factor: 5.182

4.  Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors.

Authors:  D Ogston; C M Ogston; O D Ratnoff; C D Forbes
Journal:  J Clin Invest       Date:  1969-10       Impact factor: 14.808

5.  Effect of plasma kallikrein on coagulation in vitro.

Authors:  K D Wuepper; C G Cochrane
Journal:  Proc Soc Exp Biol Med       Date:  1972-10

6.  The relation of 'Fletcher Factor' to factors XI and XII.

Authors:  W E Hathaway; J Alsever
Journal:  Br J Haematol       Date:  1970-02       Impact factor: 6.998

7.  Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties.

Authors:  W E Hathaway; L P Belhasen; H S Hathaway
Journal:  Blood       Date:  1965-11       Impact factor: 22.113

8.  Plasminoplastin generation test of normal, HF-, PTA-, X-, PTC-, and AHF- platelet-poor plasmas: evidence that only HF- plasma has an abnormal fibrinolytic activity.

Authors:  P G Iatridis; J H Ferguson
Journal:  Nature       Date:  1965-09-25       Impact factor: 49.962

9.  Plasma prekallikrein: isolation, characterization, and mechanism of activation.

Authors:  K D Wuepper; C G Cochrane
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

10.  The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

  10 in total
  35 in total

1.  Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.

Authors:  H L Meier; J V Pierce; R W Colman; A P Kaplan
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

Review 2.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Flaujeac factor deficiency. Reconstitution with highly purified bovine high molecular weight-kininogen and delineation of a new permeability-enhancing peptide released by plasma kallikrein from bovine high molecular weight-kininogen.

Authors:  R T Matheson; D R Miller; M J Lacombe; Y N Han; S Iwanaga; H Kato; K D wuepper
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

4.  Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma.

Authors:  V H Donaldson; J Kleniewski; H Saito; J K Sayed
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

5.  Potentiation of the function of Hageman factor fragments by high molecular weight kininogen.

Authors:  C Y Liu; C F Scott; A Bagdasarian; J V Pierce; A P Kaplan; R W Colman
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

6.  Association of factor XI and high molecular weight kininogen in human plasma.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

7.  Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency.

Authors:  B N Bouma; D M Kerbiriou; J Baker; J H Griffin
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

8.  The role of kallikrein in leukocyte migration inhibition.

Authors:  A M Sultan; C J Dunn; D A Willoughby
Journal:  Inflammation       Date:  1979-07       Impact factor: 4.092

9.  The activation of the alternative pathway C3 convertase by human plasma kallikrein.

Authors:  R G DiScipio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

10.  The role of kininogenases, kinin formation and kininogenase inhibition in post traumatic shock and related conditions.

Authors:  G L Haberland
Journal:  Klin Wochenschr       Date:  1978-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.